Condition: Hormone Receptor Positive Early Breast Cancer · Sponsor: Rovi Pharmaceuticals Laboratories
The study aims to compare the amount of the drug letrozole that gets into the bloodstream after multiple doses of the quarterly injection Letrozole SIE, versus multiple doses of the standard oral daily tablet of letrozole (Femara®), in women who have gone through menopause and have received treatment for hormone receptor-positive early breast cancer. Participants must have completed at least five years of hormone therapy with at least two of those years with letrozole before starting their participation in the study. Women who have completed four years of hormone therapy are also eligible if their doctor considers them at low risk of cancer returning.
This description comes directly from the study's public registry record.
Clinical Operations. Laboratorios Farmacéuticos ROVI · +34913756230 · departamento.medico@rovi.es
Always discuss trial participation with your own doctor first.
| Hospital Clínico Universitario Virgen de la Arrixaca (Investigational Site number ESP-009) | Murcia, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07401381